SHL Medical achieves EcoVadis® Silver Medal and sets ambitious science-based climate targets

SHL Medical, a world-leading provider of advanced drug delivery solutions, is a proud recipient of the prestigious EcoVadis® Silver Medal for its sustainability performance. The company received further recognition from the Science Based Targets initiative (SBTi) for its near-term emissions targets.

SHL Medical's EcoVadis® performance evaluation (69/100) reflects the company’s commitment and performance across all assessed areas: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. The result propelled the company into the top 8% companies within the drug delivery industry and the top 25% of companies across industries.   
The company recently published its new sustainability strategy, which aims to deliver positive societal impact across three key areas: enabling patients’ independence and outcomes, reducing the ecological footprint, and ensuring responsible business practices.

“Our commitment towards sustainability is deeply ingrained in every facet of our operations”, says Ulrich Faessler, CEO of SHL Medical. “We are striving to be more transparent and accountable throughout our sustainability journey and I am proud to see independent recognition of our efforts so far, showing we are headed in the right direction. We know our responsibility extends beyond the immediate horizon, and we aim to contribute long-term value for society and the environment.”

Additionally, SBTi has approved the company's science-based emissions-reduction targets for 2030:

• SHL Medical commits to reduce absolute direct (Scope 1) and indirect (scope 2) greenhouse gas emissions by 42% by 2030 from a 2022 baseline year.
• SHL Medical commits to reducing its indirect (scope 3) greenhouse gas emissions by at least 51.6% per Mio. units sold by 2030 from a 2022 baseline year.